27 January 2023
Eerste live bijeenkomst Oncode Patiënt Perspectief Programma brengt (ex-)patiënten en onderzoekers dichter bij elkaar
(Text in Dutch) Benieuwd hoe onderzoekers en (ex)patiënten elkaar kunnen helpen? Lees de highlights over Oncode's Patiënt Perspectief Programma meeting, waar onderzoekers en patiënt partners elkaar ontmoetten.
11 January 2023
Specialized immune cells carry potential for new cancer immunotherapies
Oncode Investigators Emile Voest, Ton Schumacher and Lodewyk Wessels (all NKI), together with scientists from Leiden University Medical Center (LUMC) have discovered how specialized immune cells can detect and remove cancers that are ‘invisible’ to the conventional defense mechanisms of the immune system. The findings could lead to novel cancer immunotherapies. Their work is published today in Nature.
2 January 2023
New technique to detect T cells that recognize a patient’s tumor
Oncode Investigators Emile Voest and Ton Schumacher together with Wouter Scheper (all NKI) have developed a new technique that can map out molecules on the tumor cells in individual cancer patients that are recognized by T cells. This new technology is an important step toward personalized immunotherapy. Their findings were published today in Nature Biotechnology.
15 December 2022
Overlooked immune cell proves important for impact of immunotherapy
An open mind and the courage to go off the beaten track has led Oncode Investigator Karin de Visser and medical oncologist and researcher Marleen Kok (both at the NKI) to a surprising finding. They discovered that one type of immune cell, one that cancer researchers rarely look at, is actually of great importance. Their finding could be crucial for patients receiving immunotherapy, such as breast cancer patients. Their research paper was published today in Cancer Cell.
24 November 2022
AlphaFill: filling in the blanks in protein structure prediction
The development of tools like AlphaFold and RoseTTAfold, and more recently of the ESM Metagenomic Atlas and OmegaFold, was a gamechanger in the field of 3D protein structure prediction. However, for many proteins a pivotal piece to the puzzle was still lacking, as most proteins do not function without specific cofactors. New work by the group of Oncode Investigator Anastassis Perrakis at the Netherlands Cancer Institute literally fills this void and brings AlphaFill into the picture. Their work was published today in Nature Methods.
22 November 2022
Tineke Lenstra joins the EMBO Young Investigator Programme
EMBO just announced 24 life scientists as the newest members of the EMBO Young Investigator Programme. One of the new members is Oncode Investigator Tineke Lenstra (Netherlands Cancer Institute), with her project on understanding transcriptional bursting in single cells. The Young Investigator Programme supports excellent group leaders who have been in independent positions for less than four years and have an excellent track record of scientific achievements.
18 November 2022
Oncode Institute welcomes Marvin Tanenbaum to the Research Management Committee
We are pleased to welcome Oncode Investigator Marvin Tanenbaum (Hubrecht Institute) to Oncode’s Research Management Committee (RMC). Marvin will replace Oncode Investigator Thijn Brummelkamp (NKI), who was part of the RMC for 4 years.
19 October 2022
Ruben van Boxtel receives prestigious NYSCF Robertson Stem Cell Investigator Award
The NYSCF Robertson Stem Cell Investigator Award was awarded in New York today to Oncode Investigator Ruben van Boxtel. Van Boxtel, research group leader at the Princess Máxima Center for Pediatric Oncology, will use the award to accelerate his research on the role of stem cells in the development and eventual prevention of adverse late effects in children cured of cancer. In addition to a $1.5 million prize for his research, Van Boxtel joins a network with other leading researchers in the field of stem cell biology and regenerative medicine.
Scroll for more